Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Performance Evaluation Comparison of 3 Commercially Available PCR-based KRAS

Performance Evaluation Comparison of 3 Commercially Available PCR-based KRAS RESEARCH ARTICLE Performance Evaluation Comparison of 3 Commercially Available PCR-based KRAS Mutation Testing Platforms Julia A. Adams, MD, Kristin M. Post, MPH, Sarah A. Bilbo, BS, Xiaoyan Wang, MD, Joyashree D. Sen, MD, Anita J. Cornwell, BS, Amanda J. Malek, BS, and Liang Cheng, MD outcome and response to treatment in patients with ad- Abstract: The identification of KRAS mutations in patients with vanced-stage diseases such as colorectal and lung adeno- 1–4 certain types of cancer, including colonic adenocarcinoma and carcinoma. Targeted therapies for the epidermal growth non–small cell lung carcinoma, has become increasingly im- factor receptor (EGFR), such as the monoclonal antibodies portant as these patients are contraindicated from receiving cetuximab and panitumab, have improved prognosis in pa- epidermal growth factor receptor-targeted therapies. Several tients with both colorectal and lung adenocarcinoma. polymerase chain reaction (PCR)-based tests are commercially However, these therapies are only effective in patients lack- 5–10 available for KRAS mutation testing including Applied Bio- ing an activating mutation of the KRAS gene. Approx- systems KRAS Mutation Analysis on the ABI3130xl, Qiagen imately 15% to 30% of lung and 15% to 40% of colorectal therascreen KRAS RGQ PCR on the Rotor-Gene Q MDx, and adenocarcinomas harbor the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Performance Evaluation Comparison of 3 Commercially Available PCR-based KRAS

Loading next page...
 
/lp/wolters-kluwer-health/performance-evaluation-comparison-of-3-commercially-available-pcr-XBiFx5m0qO

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2014 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PDM.0b013e3182a127f9
pmid
24614151
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Performance Evaluation Comparison of 3 Commercially Available PCR-based KRAS Mutation Testing Platforms Julia A. Adams, MD, Kristin M. Post, MPH, Sarah A. Bilbo, BS, Xiaoyan Wang, MD, Joyashree D. Sen, MD, Anita J. Cornwell, BS, Amanda J. Malek, BS, and Liang Cheng, MD outcome and response to treatment in patients with ad- Abstract: The identification of KRAS mutations in patients with vanced-stage diseases such as colorectal and lung adeno- 1–4 certain types of cancer, including colonic adenocarcinoma and carcinoma. Targeted therapies for the epidermal growth non–small cell lung carcinoma, has become increasingly im- factor receptor (EGFR), such as the monoclonal antibodies portant as these patients are contraindicated from receiving cetuximab and panitumab, have improved prognosis in pa- epidermal growth factor receptor-targeted therapies. Several tients with both colorectal and lung adenocarcinoma. polymerase chain reaction (PCR)-based tests are commercially However, these therapies are only effective in patients lack- 5–10 available for KRAS mutation testing including Applied Bio- ing an activating mutation of the KRAS gene. Approx- systems KRAS Mutation Analysis on the ABI3130xl, Qiagen imately 15% to 30% of lung and 15% to 40% of colorectal therascreen KRAS RGQ PCR on the Rotor-Gene Q MDx, and adenocarcinomas harbor the

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Mar 1, 2014

There are no references for this article.